CANADA: 3D Bioprinted Lung Tissue Could Eliminate Need For Lung Transplants By Growing New Vessels

Canadian Team Bioprints lung Tissue Aimed At Reducing Need For Transplantation

WORLD NEWS – CANADA: Researchers at the McGill University Health Centre are developing 3D‑printed lung tissue as an alternative to full lung transplantation, responding to a severe shortage of donor organs and poor outcomes for recipients. Bioengineer Dr. Darcy Wagner is leading work that targets the chronic gap between demand and supply: roughly 7,000 lung transplants occur worldwide while millions remain on waiting lists, and lungs currently have some of the worst results among solid‑organ transplants.

The approach uses living cells suspended in a body‑compatible polymer that solidifies when activated by a chemical trigger. Wagner and her team have tailored the printing materials specifically for pulmonary tissue rather than adapting existing bioprints. According to the researchers, the scaffold design encourages the patient’s own blood vessels to grow into the implant, a property intended to integrate the construct with native lung and support function after placement.

Early laboratory studies in mice have been described as promising, with the team reporting an absence of the adverse response that typically limits implanted lung material. The group emphasizes that this lung‑specific 3D bioprinting could be used to rebuild localized airway or lung sections instead of replacing an entire organ. In cases such as tumors that invade only part of a lung, the technique aims to reconstruct the damaged region while preserving the healthy remainder, potentially avoiding transplantation for many patients.

Officials at the McGill centre frame the project as a step toward more personalized respiratory medicine, tailoring therapies to individual biology and circumstances. Dr. Alan Forester, head of innovations, identified financing as a major barrier to bringing the technique from bench to bedside, calling for insurance reform and new partnerships to support translational research. The team is positioning the work as an innovation that could reshape options for patients facing lung failure or focal pulmonary disease.